Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Baxter International Inc    BAX

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Baxter International Inc. : Baxter's Investigational Hemophilia Treatment Yields Positive Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/10/2012 | 03:34pm CET
    By Saabira Chaudhuri 
 

Baxter International Inc. (BAX) said results from a study evaluating its investigational treatment for patients with hemophilia B were positive.

The medical product company's BAX 326--its investigational recombinant factor IX protein for the treatment and prophylaxis of bleeding episodes for patients with hemophilia B over 12 years of age--was recently granted orphan-drug designation by the U.S. Food and Drug Administration.

"With only one recombinant protein currently available to treat hemophilia B, it was important to focus research efforts on finding another option for patients with this debilitating disease," Lead Investigator Jerzy Windyga said. "In this study, more than 40 percent of patients using BAX 326 as a prophylactic treatment experienced no bleeds, an important finding given the potentially harmful impact of bleeding episodes for patients."

The study investigated the efficacy and safety of BAX 326 in 73 previously treated patients with severe or moderately severe hemophilia B.

Baxter noted that hemophilia B is the second most common type of hemophilia--also known as Christmas disease--and is the result of insufficient amounts of clotting factor IX, a naturally occurring protein in blood that controls bleeding. The company added that about 25,000 people world-wide, including more than 4,000 in the U.S., have been diagnosed with hemophilia B.

Baxter's profits have improved for more than a year on strong demand for its hemophilia and immunodeficiency products. Its bottom line has been less pressured by the slowdown in health-care spending, compared with some peers, because Baxter focuses on medical devices and pharmaceuticals used to treat life-threatening ailments and injuries.

In October, Baxter said its third-quarter earnings rose 1.2% as the company's margins improved, though sales were short of its prior guidance.

Shares closed Friday at $65.07 and were inactive in recent premarket trading. The stock has risen 32% so far this year.

Write to Saabira Chaudhuri at saabira.chaudhuri@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAXTER INTERNATIONAL INC
12/01 BAXTER INTERNATIONAL : Presented Exploratory Research on the Removal of Inflamma..
12/01 BAXTER INTERNATIONAL : New Data Presented at ASN Kidney Week Spotlight Baxter's ..
11/30 BAXTER INTERNATIONAL INC : ex-dividend day
11/29 BAXTER INTERNATIONAL : Americares and Baxter International Foundation Announce O..
11/22 BAXTER INTERNATIONAL : Patent Issued for Dialysis Bag with Anti-Occlusion Featur..
11/22 BAXTER INTERNATIONAL : United Way of Lake County Strengthens Program Providing A..
11/22 BAXTER INTERNATIONAL : to Present 24 Abstracts at ASN Kidney Week 2016 Focused o..
11/22 BAXTER INTERNATIONAL : Presented Exploratory Research on the Removal of Inflamma..
11/21 BAXTER INTERNATIONAL : New Data Presented at ASN Kidney Week Spotlight Baxter's ..
11/21 BAXTER INTERNATIONAL : New Data Presented at ASN Kidney Week Spotlight Baxter&rs..
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
11/22DJMEDTRONIC : Cuts Guidance on Sluggish Revenue
11/22DJMEDTRONIC : Cuts Guidance on Sluggish Revenue -- 2nd Update
11/22DJMEDTRONIC : Cuts Guidance on Sluggish Revenue
11/15 EXCLUSIVE : EU regulators seen clearing $25 billion Abbott, St Jude deal
11/15 Exclusive - EU regulators seen clearing $25 billion Abbott, St Jude deal
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
11/25 Tracking Tweedy Browne Portfolio - Q3 2016 Update
11/21 Why We Love Insider Buying And You Should Too
11/14 Tracking Dan Loeb's Third Point Portfolio - Q3 2016 Update
11/08 Baxter declares $0.13 dividend
11/02 Baxter initiates late-stage study of novel therapy for acute kidney injury
Advertisement
Financials ($)
Sales 2016 10 175 M
EBIT 2016 1 347 M
Net income 2016 1 604 M
Debt 2016 221 M
Yield 2016 1,18%
P/E ratio 2016 4,50
P/E ratio 2017 22,45
EV / Sales 2016 2,37x
EV / Sales 2017 2,26x
Capitalization 23 938 M
More Financials
Chart BAXTER INTERNATIONAL INC
Duration : Period :
Baxter International Inc Technical Analysis Chart | BAX | US0718131099 | 4-Traders
Full-screen chart
Technical analysis trends BAXTER INTERNATIO...
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 16
Average target price 53,3 $
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
José E. Almeida Chairman, President & Chief Executive Officer
Scott Pleau Vice President-Operations
James K. Saccaro Chief Financial Officer & Vice President
Paul E. Martin Chief Information Officer & Vice President
Marcus Schabacker Chief Scientific Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BAXTER INTERNATIONAL I..14.36%23 938
MEDTRONIC PLC-6.38%99 513
ZIMMER BIOMET HOLDINGS..-2.33%20 070
C R BARD INC10.83%15 438
HOYA CORPORATION-9.17%15 327
TERUMO CORP7.41%13 328
More Results